Latest Articles
Hutchmed’s Promising Phase III Study on Advanced Endometrial Cancer Treatment - MSN
Hutchmed’s Promising Phase III Study on Advanced Endometrial Cancer Treatment MSN
Published: Oct. 30, 2025, 10:54 a.m.
Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study - MSN
Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study MSN
Published: Oct. 30, 2025, 10:49 a.m.
COMMENTARY: Early cancer detection, with new tools and genetic testing, saves lives - Jefferson City News Tribune
COMMENTARY: Early cancer detection, with new tools and genetic testing, saves lives Jefferson City News Tribune
Published: Oct. 30, 2025, 9 a.m.
Symptoms of endometrial cancer recurrence: Watch out for unusual weight loss, bleeding, pain, nausea - Moneycontrol
Symptoms of endometrial cancer recurrence: Watch out for unusual weight loss, bleeding, pain, nausea Moneycontrol
Published: Oct. 30, 2025, 8:35 a.m.
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability - MSN
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability MSN
Published: Oct. 30, 2025, 4:04 a.m.
'Doctors misdiagnosed me with cancer — they apologized after my hysterectomy' - MSN
'Doctors misdiagnosed me with cancer — they apologized after my hysterectomy' MSN
Published: Oct. 30, 2025, 2:56 a.m.
Insights into endometrial cancer management: a comprehensive guide through multimodality imaging - springermedicine.com
Insights into endometrial cancer management: a comprehensive guide through multimodality imaging springermedicine.com
Published: Oct. 29, 2025, 10:52 p.m.
Early cancer detection, with new tools and genetic testing, saves lives - Qatar Tribune
Early cancer detection, with new tools and genetic testing, saves lives Qatar Tribune
Published: Oct. 29, 2025, 9 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - BioSpace
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer BioSpace
Published: Oct. 28, 2025, 5:03 a.m.
Genmab’s New Phase 3 Study: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks
Genmab’s New Phase 3 Study: A Potential Game-Changer in Endometrial Cancer Treatment TipRanks
Published: Oct. 27, 2025, 11:43 p.m.
Link copied to clipboard!